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Despite recent and potent technological advances, the real-world implementation of remote digital health technology in the care
and monitoring of patients with motor neuron disease has not yet been realized. Digital health technology may increase the
accessibility to and personalization of care, whereas remote biosensors could optimize the collection of vital clinical parameters,
irrespective of patients’ ability to visit the clinic. To facilitate the wide-scale adoption of digital health care technology and to
align current initiatives, we outline a road map that will identify clinically relevant digital parameters; mediate the development
of benefit-to-burden criteria for innovative technology; and direct the validation, harmonization, and adoption of digital health
care technology in real-world settings. We define two key end products of the road map: (1) a set of reliable digital parameters
to capture data collected under free-living conditions that reflect patient-centric measures and facilitate clinical decision making
and (2) an integrated, open-source system that provides personalized feedback to patients, health care providers, clinical researchers,
and caregivers and is linked to a flexible and adaptable platform that integrates patient data in real time. Given the ever-changing
care needs of patients and the relentless progression rate of motor neuron disease, the adoption of digital health care technology
will significantly benefit the delivery of care and accelerate the development of effective treatments.
(J Med Internet Res 2021;23(9):e28766) doi: 10.2196/28766
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Introduction
Remote digital health technology, ranging from simple mobile
apps to implantable devices, will reform the delivery of care.
Despite the recent technological advances in biosensors, mobile
communications, and cloud computing, their real-world
implementation remains to be fully realized [1]. Motor neuron
disease (MND) is a debilitating disorder in which digital health
care technology will benefit delivery of care [2,3] and also
expedite the development of effective treatments [4-6]. Patients
living with MND rapidly lose their functional independence,
making travel, communication, and visits to specialist clinics
for assessment of vital clinical parameters challenging [7]. This
has been particularly the case during the COVID-19 pandemic
[8,9]. The effects of the pandemic have focused attention on
technological advances that increase the accessibility and
personalization of care, and remote biosensors that optimize
the collection of vital clinical parameters, irrespective of the
patients’ ability to visit the clinic, are poised to revolutionize
the clinical encounter. These developments hold benefits for
both research and care settings, driving the implementation of
real-world use of remote digital health care technology in MND
[2,10].
Notwithstanding, the following key barriers delay the adoption
and wide-scale implementation of digital health care technology
in MND [2]: (1) technical complexities, (2) low compliance
rates, (3) time investment required, (4) high costs, and (5)
legislation challenges. For clinical trials, adoption is further
complicated by regulatory hurdles because of reduced
auditability, consistency, and data quality [6,11,12]. Although
there is considerable work underway in these areas that will
facilitate the validation and initial adoption of digital technology
in MND [4,5,13-15], it is also the case that device or platform
incompatibility might further delay their wide-scale adoption
and large-scale data aggregation. Therefore, there is a recognized
need to open collaborations among clinicians, engineers, and
technology companies that will support early implementation.
Here, we outline a road map that aims to (1) facilitate the
identification of clinically relevant digital parameters; (2)
mediate the development of benefit-to-burden criteria for
innovative technology; and (3) direct the validation,
harmonization, and adoption of digital health care technology
in real-world settings.
The Need for Remote Technology in MND
Disease heterogeneity and rapid physical deterioration are key
drivers in the delivery of care and monitoring of disease
progression in clinical trials. Although MND is recognized as
a clinical entity, it is better considered as a number of different
subgroups with variable clinical presentations, different causes,
and different disease trajectories. A flexible approach toward
management is required such that the patient’s clinical condition
is monitored at intervals that best reflect both the needs of the
patient and their family and the trajectory of the disease. As
progression ultimately leads to severe disability, clinical
attendance is increasingly burdensome [16], notwithstanding
the known benefits of multidisciplinary clinics that include
survival and optimal access to assistive devices or proven
treatments [17]. Unfortunately, even in developed countries,
attendance at multidisciplinary clinics is as low as 43%, and
many of those who can attend are unable to return [18].
We illustrate the extent of this attrition process, as observed in
a large clinical trial [19], in Figure 1. From the point of trial
enrollment, almost 1 in 4 (184/750, 24.5%) patients failed to
visit the clinic after 12 months, and more than one-third
(271/750, 36.1%) were unable to provide reliable respiratory
information. These figures are likely an underestimation of the
attrition rates occurring at multidisciplinary clinics because
clinical trials select for patients with better prognoses [20,21].
These high attrition rates affect the estimation of treatment
benefit within clinical trials, reduce statistical power, and may
lead to the continuation of an ineffective compound into a
subsequent phase of clinical development.
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Figure 1. Percentage of EMPOWER patients with missing information on clinical outcome measures. For each clinical visit in the EMPOWER study,
we determined the number of patients that were on study medication and were alive (ie, number at risk). Subsequently, we calculated the proportion of
missing observations per outcome measure. If the patient was no longer able to visit the clinic (as indicated by the number of missing in-clinic muscle
strength assessments), ALSFRS-R data and blood samples were collected remotely by home visit or by phone. ALSFRS-R: Amyotrophic Lateral
Sclerosis Functional Rating Scale-Revised.
Figure 1 also demonstrates that outcomes that can be measured
remotely, either by phone for the Amyotrophic Lateral Sclerosis
Functional Rating Scale-Revised (ALSFRS-R) or by a home
visit for a blood sample, can reduce attrition and may mitigate
many of the current challenges. Remote data collection can be
tailored to identify and accommodate the ongoing needs of
patients and caregivers, thus shortening the time spent at the
hospital or traveling to the hospital and personalizing visiting
schemes [14,22]. This in turn can provide a communication
channel between patients and health care providers that builds
an iterative and shared decision-making process regarding the
timing and management of interventions and the approaches to
end of life [23]. For clinical trials, home-based monitoring of
disease progression is likely to more accurately reflect the
patients’ true physical condition in free-living (ie, nonclinical)
settings and lower the burden of monitoring. This in turn is
likely to increase the number of patients who can participate in
clinical research and provide real-world insight into the
therapeutic value of experimental drugs [6,11,24]. Designing
an information source that reflects the patients’ true physical
condition in near real time is therefore of significant value for
all stakeholders.
A Road Map for MND
In this paper, we considered technology that assists with remote
monitoring of MND disease progression or identifies critical
health issues such as the development of respiratory or
nutritional failure. To that end, we defined two key end products
of the road map, as follows:
1. A set of reliable digital parameters to capture data, collected
under free-living conditions at the patient’s home, that
reflect patient-centric measures and facilitate clinical
decision making
2. An integrated open-source system that provides
personalized feedback to patients, health care providers,
clinical researchers, and caregivers
To achieve this, there is a need for input from all stakeholders,
including those living with MND and those who (informally)
care for patients with MND. To promote the uptake of new
technology in real-world settings, we used a user-centered
co-design approach that involves input from stakeholders (eg,
patients, caregivers, physicians, ethicists, regulators,
programmers, and researchers) at every stage of development
[25]. There will be specific attention paid to patient, caregiver,
and researcher access as well as international regulatory,
financial, and licensing hurdles to ensure widespread
implementation, sustainability, and growth [26]. For this road
map, we have identified the following three key questions: (1)
what to measure; (2) how to measure; and (3) how to
implement? We outlined the requirements to answer each of
these questions, considering the needs of the various
stakeholders of the technology.
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Patient centricity is crucial to promote long-term adherence,
where end points should focus on how aspects of MND affect
daily living and distinguish between symptoms (ie, impairments)
and activities (ie, disabilities). The clinician’s input may help
to prioritize end points in clinically relevant domains or
supplement other aspects of MND that patients may not
recognize as clinically important (eg, weight loss or cognitive
and behavioral changes). This approach maximizes the
likelihood of acquiring data that facilitate clinically relevant
decision making and minimizes the collection of redundant
information.
Workplan: What to Measure?
Information will be collected from three independent sources:
(1) a systematic literature review summarizing and
meta-analyzing all published symptomology associated with
MND; (2) face-to-face in-depth interviews and focus group
discussions with patients, caregivers, and physicians until data
saturation is reached; and (3) a cross-sectional, population-based
patient survey. We will apply a purposive and theoretical
sampling strategy to ensure that we capture the complete range
of disease patterns reported among patients with MND [27].
Videoconferencing will be used to ensure full patient
participation at all meetings. In Figure 2, we illustrate two key
elements that may help to disentangle the clinical heterogeneity
observed among patients and guide sampling strategies or
evaluate generalizability: clinical disease stage and progression
rate. Some symptoms such as speech disturbances may only be
prevalent in early clinical stages and will disappear over time
owing to a complete loss of function (illustrated as Symptom
A). Conversely, some symptoms may only be prevalent in
patients with a certain disease type or progression rate (eg,
symptoms related to spasticity in a primarily upper motor
neuron, a slowly progressing subtype of disease, illustrated as
Symptom B). Mapping the prevalence of symptoms in this 2D
plane may help to disentangle a large part of the clinical
heterogeneity in MND. Clinical stage can be defined by the
King’s clinical and Milano-Torino functional staging algorithms
[28,29], whereas the progression rate is directly related to
survival time and could be mapped by, for example, the patient’s
predicted prognosis [30].
Figure 2. Untangling clinical heterogeneity in motor neuron disease in a 3D framework. The prevalence of symptoms as reported by patients will be
mapped according to their clinical stage and (predicted) progression rate. Clusters of symptoms will be defined into domains (eg, bulbar, motor,
respiratory, and cognition) for creating a 3D map of motor neuron disease symptom heterogeneity. The map will be used to identify clinically relevant
and targetable end points. ALS: amyotrophic lateral sclerosis.
A complete list of symptoms will be extracted from the
interviews and focus group meetings, supplemented with data
from the literature review, and by language processing and text
mining from a population-based, cross-sectional survey asking
open questions such as “What bothers you the most about your
MND” and “In what way does this affect your daily living?”
Information collection will be conducted in a multicenter,
international setting to account for potential geographical, social,
and cultural differences. Finally, a large range of statistical
methods will be used for pattern recognition to cluster targets
and end points, identify redundant information, and classify
subgroups of patients with specific needs. Ultimately, this results
in a 3D framework, as depicted in Figure 2, that orders a large
part of the variability in symptoms among patients. Additional
classification using, for example, cognitive or behavioral
impairment or the presence of dementia may be applied to
further elucidate heterogeneity in MND [31,32]. The 3D
framework could help to evaluate the representativeness of the
included population and quickly identify clinically relevant and
targetable end points. The final list of targetable end points will
be evaluated by patients, caregivers, and physicians for further
refinement and prioritization.
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The second step is to translate the list of clinically relevant
aspects of MND into digital parameters. For example, speech
is a clinically relevant outcome in which a mobile speech app
could serve to improve its objective assessment in a standardized
manner. Critical aspects to consider here are, among other
things, whether the mobile app requires an action-dependent or
passive task (eg, repeat a fixed sentence vs record a daily 5-min
conversation), the uniformity and precision of the digital voice
parameters (eg, speaking rate vs volume vs perturbations) [33],
the required number and length of measurements (eg, daily,
weekly, or monthly follow-up), and whether direct supervision
or caregiver assistance is required. These factors not only
determine the burden for patients or caregivers but also establish
the value of the obtained information for researchers and health
care providers. The aim is to define selection criteria for digital
technology that evaluates burden-to-information ratios and,
based on these criteria, results in a standardized and protocolized
set of digital metrics for MND.
Workplan: How to Measure?
We will conduct a series of systematic reviews to define a list
of candidate technologies for each targetable aspect of MND.
Naturally, the real-world use of the suggested technology could
reveal insights that may not have been reported previously in
the literature or by the supplier. Longitudinal studies are
preferred because they not only evaluate test-retest reliability
and the validity to capture disease progression of a digital
parameter but they also provide information on patient
adherence and the adequacy of the monitoring protocol (eg,
obtaining daily, weekly, or monthly measurements). The latter
is an often-overlooked aspect, although it has important
consequences for all stakeholders. Naturally, a daily monitoring
scheme would provide the most information about the disease
for health care providers and researchers [5] but could
disproportionally increase patient burden and lead to high
(differential) attrition. A periodic monitoring scheme may be
more successful, and a data-driven optimization of this trade-off,
while accounting for patient and health care provider
preferences, should be used.
As a practical illustration, in Table 1, we show the benefit of
changing the monitoring frequency from monthly to daily for
two end points: ALSFRS-R and daily physical activity [4]. The
benefit of more or less frequent monitoring strongly depends
on the end point, and as demonstrated by the ALSFRS-R, it
could be questionable whether high-frequency monitoring is
always beneficial. In addition, because of a difference in
progression rates among patients, the monitoring frequency
could be further optimized for each individual patient (eg, a
patient who slowly progresses may require less frequent
monitoring). Ultimately, the optimal monitoring scheme is likely
to differ from digital end point to end point, and longitudinal
data are essential to estimate a data-driven optimal
burden-to-information ratio for each device or mobile app [4].
















aDaily activity was defined as the proportion of time that the patient was nonsedentary, as described elsewhere [4]. Sample size calculations are based
on a standardized linear mixed model; data are based on 42 patients [4]. Sample size calculations assumed a target power of 80%, 2-sided α of 5%, and
a 25% reduction in the progression rate; numbers are the required sample size per group [34].
bProgression rate is expressed as number of SD per month. Both the ALSFRS-R and daily activity were standardized to make a direct comparison
possible. The ALSFRS-R has, on average, a faster progression rate, more variability between patients, and less variability within patients compared
with daily activity.
cref: reference.
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There are circumstances in which digital technology may not
appropriately quantify disease symptoms (eg, changes in mood
or alterations in cognition). Therefore, an important aspect of
the road map is to additionally develop scales and questionnaires
that can be administered remotely to quantify clinically relevant,
subjective symptoms [35]. It is important for these patient- and
caregiver-reported outcome measures to consider elements such
as the ease of engagement (eg, mobile apps with multiple verbal
and nonverbal response formats), the length of questionnaires,
the validity of questions (eg, differences between
patient-reported and in-clinic outcomes), and the viability for
digitization. Ultimately, it may prove critical to harmonize and
integrate passive digital methods such as accelerometry with
task-dependent methods and questionnaires to derive the most
reliable and representative state of disease at any given time.
In addition, an important goal is to maximize the adherence and
retention of the patient or caregiver. In two studies that reported
on remote monitoring with personalized feedback in care
settings [14,22], 80%-87% of the patients provided regular
ALSFRS-R information. In two recent studies that solely
monitored disease progression without providing care, this was
reduced to 24%-56% [15,36]. It seems critical to provide an
incentive to participate, where patients do not simply upload
their data into the cloud but also receive something in return,
such as care, tailored information, or personalized insights. An
understanding of how best to retain patients in the digital
environment (eg, by incorporating behavioral or motivational
techniques) and which patient factors are related to digital uptake
or adherence are fundamental to the success of the workplan.
Finally, it is important to consider the geographical region and
the local facilities and demographics. Older populations or
patients from developing areas with minimal financial,
technological, or educational facilities may encounter challenges
when using devices. This could increase the risk of care
asymmetries across populations and should be considered when
comparing candidate technologies.
How to Implement?
A standardized format or platform for multiple digital metrics
is not yet available, and a priority of the Treatment Research
Initiative to Cure ALS will be to provide this technology [37].
This platform will solve the problem of collecting data relating
to multiple domains while using multiple apps from different
providers. Such a platform is essential because clinical decision
making is often multidimensional and requires insight into
various aspects of the patient simultaneously. The aim of this
final part of the road map is to (1) integrate different data
sources required by the end users and (2) deploy an open-source
framework product in which one can flexibly integrate different
third-party solutions, evaluate the performance of digital metrics
compared with clinically relevant events, and allow in-depth
analysis of health care expenditures and outcomes.
Workplan: How to Implement?
In Figure 3, we schematically illustrate the final product. The
first step would be to standardize the metrics that are of interest
across different devices. The standardized metrics are
subsequently stored in a central database that acts as a single
integrative platform. The capability of the device to allow
uninterrupted, remote data access is therefore critical; the final
selection of devices or mobile apps is likely an iterative process
in close relationship with the How to Measure section. Although
the concept is simple, this part of the road map may be the most
challenging because of, among other things, privacy, regulatory,
ethical, ownership, licensing, certification, and database
challenges. A close collaboration among various industry,
academic, funding, and regulatory parties has been initiated to
provide a clear central and local governance and management
structure with meticulous planning.
The next step is to translate the centralized data into useful
information and disseminate insights to the relative end user.
Given the extent of information acquired and the number of
different stakeholders and settings, a customized approach will
be required. Where a trialist may be primarily interested in a
historical benchmark of group averages, clinicians and patients
will be principally interested in individual disease patterns.
These interests need to be carefully documented, and a dynamic,
user-centered co-design approach is vital. It is important to
evaluate how the implementation of digital parameters affects
existing standard operating procedures and work practices or
how health care professionals adhere to new MND technologies
[38]. For care purposes, defining optimal activation or flagging
rules is important for timely activation of additional care. For
example, thresholds are needed for respiratory function (or
decline in function) to alert the patient’s health care provider
or automatically refer the patient to a pulmonologist when the
threshold is reached. Defining these rules can help to standardize
remote monitoring of MND, and this requires the development
of a disease-specific protocol based on MND guidelines and
expert opinions [14].
In addition, efforts are required to evaluate different strategies
for effective communication among users, for example, the
implementation of chat functions between patients and health
care providers or the provision of personalized information or
feedback on the obtained measurements. By making use of
open-source software platforms, tailored programs can be
developed in a dynamic interface, while seamlessly integrating
the continuously updating information from wearables and
mobile apps. We have previously provided an example of such
a platform for clinical trial design [39]. The platform and
interactive platform will go through several stages before the
product can be finalized, for example, prototype development,
iterative testing phases, experimenting with varying key
parameters (eg, user burden, monitoring frequency, different
wording and timings, and different prompting regimes), pilot
releases, and upgrading, taking into account the input from all
users at every stage.
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Figure 3. The harmonization and centralization of digital outcome data before dissemination. A schematic illustration of the integration of different
devices from different third parties into a central database that acts as a single integrative platform is illustrated for vital capacity and accelerometry.
Information and insights can subsequently be disseminated interactively to the respective end users.
Finally, only by real-world implementation can the true value
of digital parameters and platforms be evaluated. For care
settings, it is important to conduct dedicated studies to evaluate
the cost-effectiveness of the digital health care technology and
its effect on clinical outcomes. The gold standard would be
randomized controlled trials, for example, allocating patients
to usual care or digital assisted care or allocating hospitals in a
cluster randomized study. An example of the former has been
published previously, in which the authors evaluated the effect
of home telemonitoring of noninvasive ventilation on the
number of hospital visits [40], together with its
cost-effectiveness [41]. Given the complexity of most eHealth
interventions [13], such trials are challenging and it may not be
immediately clear what an ideal efficacy end point would be
(eg, survival time, number of hospital admissions, costs, or
patient-reported indicators?). A key aspect for successful uptake
is to have a financial model that is sustainable, while providing
clinically relevant benefits to all stakeholders.
For clinical trials, the cost aspect may be of similar importance,
and studies evaluating the gain in retention compared with cost
would be highly insightful. Besides the potential reduction in
attrition rates and gain in information quality, it will be
necessary to determine whether digital metrics can ultimately
replace the clinical efficacy end point (ie, surrogacy) and
increase trial efficiency. The real-world systematic use of digital
health care technology, alongside common clinical efficacy
endpoints, is therefore a key first step. The potential use of
real-world data originating from digital health care technology
in clinical drug development has been recognized for regulatory
purposes [42]. Nevertheless, important challenges remain, such
as the design of interventional studies and challenges related to
data availability, data quality, auditability, and the completeness
of electronic phenotyping [43].
Data Security and Privacy Regulations
Given the current data security and privacy regulations for
medical devices and personal data (eg, General Data Protection
Regulation), data security and ethical hurdles will have a major
impact on the developmental and operational aspects of the
platform and on how the data may be used during (international)
research projects or within care settings. These aspects are not
only important for the platform itself but also apply to, for
example, cloud services from third parties. How, when, and by
whom data can be accessed need to be tailored and defined for
each participating site individually to comply with local laws
and regulations. Making use of existing infrastructures, for
example, by integrating the platform into eHealth care services
and requiring two-factor authentication could facilitate secure
data access [14], but its feasibility depends on the available
local facilities. In addition, considerations for using the data
include obtaining consent to (1) share personally identifiable
information for direct care only, (2) share personally identifiable
information for research and care purposes, or (3) share
anonymized data to be used for research only. Similarly, there
is a need to address challenges in intellectual property and data
ownership (eg, where the demarcation might be made between
clinical and technical intellectual property).
An important consideration is the CE (Conformité Européenne)
marking for medical devices and software. The disadvantage
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of CE marking an entire ecosystem, as presented in Figure 3,
is that it may significantly constrain the rate of change and
evolution of the system. CE marking locks down the design,
and any significant changes made to the system (eg, addition
of new algorithms or devices) requires reapproval by external
regulatory bodies. A consideration could be to use a mixed
approach of using CE-marked devices and algorithms
interconnected and facilitated by non–CE-marked software.
This will require some design constraints to make it possible
(eg, there can be no opacity in terms of non–CE-marked
algorithms supporting clinical decision making), and achieving
this goal will require careful design and partitioning from the
outset. Another strategy is to consolidate and rationalize into a
single CE-marked system once the ecosystem for ALS, including
measurements, algorithms, and protocols, reaches maturity.
These challenges will require dedicated strategies, which will
need to be developed with the involvement of all relevant
stakeholders and by obtaining expertise from ethicists,
regulators, and data privacy officers. Ultimately, these
discussions may affect the choice of measurement or device,
indicating that the final set of digital parameters for MND is
likely defined during a dynamic and iterative process rather
than being fixed from the outset.
Conclusions
In conclusion, this road map aims to align the current
developments in digital health care technology for MND and
initiate a collaborative effort to mediate its wide-scale adoption
across MND clinics and clinical trials. We defined the following
three key questions, the answers to which are critical to achieve
this aim: (1) what to measure; (2) how to measure; and (3) how
to implement? Each question requires a dedicated study
methodology to overcome potential implementation, adoption,
or regulatory hurdles, which are summarized in Table 2.
Table 2. Summary of the road map for remote digital health technology for motor neuron disease (MND).
ResultMethodAimQuestion
List of targetable end points for
MND
To define clinically relevant,
patient-centric, and targetable
aspects of MND
What to measure? • Inventorying symptomology associated with MND
by systematic literature review, face-to-face in-depth
interviews, focus group discussions, and population-
based patient surveys
Set of standardized and proto-
colized digital metrics
To translate targetable end
points for MND into digital pa-
rameters
How to measure? • Candidate technologies are identified by systemic lit-
erature reviews. Standardized longitudinal studies are
initiated to evaluate test-retest reliability and validity
to capture disease progression and to assess protocol
adherence.
Scalable and validated platform
to provide tailored information
for care and research settings
To centralize digital metrics in
an integrative platform and
disseminate user-dependent in-
formation
How to implement? • Create a single database using open-source software
platforms, reactive programming, and third-party
cloud services
• Initiation of dedicated studies to evaluate health care
expenditures, cost-effectiveness outcomes, and surro-
gate biomarker value
Given the ever-changing care needs of patients and the relentless
progression rate of MND, aligning our current endeavors and
facilitating the adoption of digital health care technology will
significantly benefit the delivery of care and accelerate the
development of effective treatments against this debilitating
disease.
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ALS: amyotrophic lateral sclerosis
ALSFRS-R: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised
MND: motor neuron disease
CE: Conformité Européenne
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